Human Antitetanus Immunoglobulin

Human Antitetanus Immunoglobulin (HATI) is a laboratory-derived medication obtained from plasma of immunized human donors. It is specifically designed to provide immunity against the bacterium responsible for tetanus, or lockjaw. The protective antibodies present in HATI are used to prevent and treat infection from this bacterium, which may enter the body through wounds and cause severe muscle stiffness and convulsions.
HATI is an essential component of emergency care, particularly in cases of deep injuries or wounds with significant contamination. It is also recommended for individuals receiving tetanus-prone vaccinations or those with exposure to tetanus bacteria. The use of HATI significantly reduces the risk of developing complications and aids in successful recovery from tetanus.
Prioritize proper wound care and vaccinations to minimize the need for HATI. Healthcare professionals should always advocate for timely medical interventions and adherence to vaccine schedules to ensure patient safety and avoid tetanus infections.